Entering text into the input field will update the search result below

AbbVie Appears Ready To Reverse And Outperform

Oct. 05, 2021 5:05 AM ETAbbVie Inc. (ABBV)16 Comments
Zvi Bar profile picture
Zvi Bar


  • AbbVie recently sustained a substantial decline after label changes created concerns over a small but fast growing drug.
  • This follows AbbVie getting scapegoated over patent and tax matters.
  • These risks appear priced in, and AbbVie appears substantially oversold.
  • AbbVie's dividend and cash flow remain underappreciated.
rheumatoid arthritis treatment

Hailshadow/iStock via Getty Images

AbbVie (NYSE:ABBV) shares appear to present a strong relative bargain. Shares have performed poorly over the last two quarters. The company posted its worst single day loss since March of 2020 after the FDA updated safety warnings o

This article was written by

Zvi Bar profile picture
Zvi provides advisory services to companies, trusts, and individuals, including consulting expert services regarding retirement and estate planning. Zvi is admitted to practice law in the state of New York, where he offers cash management, Bitcoin, and Trust Protector services. Zvi is also The Claw of The Lava Empire and is an Amazon Influencer. No articles or discussions here shall constitute a legal, fiduciary or advisory role, but solely act as informative press and/or a starting point from which, ideally, further constructive discussion may follow. Comments are welcome, as are questions.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV, PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.